- ICH GCP
- Yhdysvaltain kliinisten tutkimusten rekisteri
- Kliininen tutkimus NCT07945379
Cytomegalovirus Infection After Transplantation: a Study of New Markers to Optimize the Selection of Antiviral Therapies and Reduce the Risk of Developing Direct and Indirect Infection-related Complications (CMV-TX-2025)
Background and Rationale Cytomegalovirus (CMV) remains a major cause of morbidity and mortality in recipients of solid organ transplantation (SOT) and hematopoietic stem cell transplantation (HSCT). Current management relies on antiviral prophylaxis or pre-emptive therapy guided primarily by CMV-DNAemia monitoring. However, recently introduced antivirals such as letermovir and maribavir have changed the virological profile of CMV infection, highlighting limitations of DNAemia as a marker of active viral replication and increasing the need for improved resistance monitoring.
Preliminary studies suggest that CMV-RNAemia (UL21.5 mRNA) may be a more accurate marker of active viral replication and may detect viral clearance approximately 7-14 days earlier than CMV-DNAemia. In parallel, Next Generation Sequencing (NGS) may provide superior detection of antiviral resistance mutations, including low-frequency variants that cannot be identified by conventional Sanger sequencing.
Primary Objective To determine whether using CMV-RNAemia to guide discontinuation of antiviral therapy in transplant recipients can reduce treatment duration and drug-related toxicity without increasing the risk of CMV relapse, compared with the current standard based on CMV-DNAemia.
Secondary Objectives
Compare the diagnostic performance of NGS and Sanger sequencing in detecting CMV antiviral resistance mutations.
Estimate the incidence of resistant or refractory CMV infection (R/R-CMV) in transplant recipients.
Identify risk factors associated with the development of R/R-CMV according to transplant type.
Study Design This is a single-center, pragmatic, randomized controlled interventional study conducted at the IRCCS Azienda Ospedaliero-Universitaria di Bologna.
Adult transplant recipients (≥18 years) with CMV infection requiring antiviral therapy will be randomized (1:1) into two groups:
Experimental arm: antiviral therapy discontinued after two consecutive negative CMV-RNAemia results.
Control arm: antiviral therapy discontinued after two consecutive negative CMV-DNAemia results.
Patients will be followed from treatment initiation, with virological monitoring continuing during therapy and follow-up.
Population and Sample Size The study plans to enroll approximately 330 CMV infection episodes, including an estimated 10% drop-out rate, with 150 participants per study arm plus additional cases to compensate for losses.
Endpoints Primary endpoints include:
Time to treatment discontinuation. Time to viral clearance. Incidence and timing of clinically significant CMV relapse. Antiviral drug toxicity.
Secondary endpoints include:
Sensitivity, specificity, and predictive value of NGS versus Sanger sequencing. Incidence of resistant/refractory CMV infection. Identification of clinical and virological risk factors for resistance.
Resistance Analysis In suspected resistant or refractory CMV infections, residual biological samples will undergo NGS analysis targeting CMV genes involved in antiviral resistance (UL97, UL54, UL56, UL89, UL27, UL51). Results will be compared with standard Sanger sequencing to assess earlier detection of resistance mutations and minor viral variants.
Expected Impact The study aims to establish CMV-RNAemia as a clinically useful marker for earlier identification of viral clearance, enabling shorter antiviral treatment and reduced toxicity. It also seeks to validate NGS-based resistance testing as a more sensitive tool for detecting emerging CMV drug resistance, ultimately supporting a more personalized approach to CMV management in transplant recipients and potentially other immunocompromised populations.
Study Duration and Funding The study is expected to last 24 months (18 months recruitment, 4 months follow-up, 2 months analysis) and is funded by the Italian Ministry of Health (Ricerca Corrente 2026, project RC-2026-2802099).
Tutkimuksen yleiskatsaus
Tila
Interventio / Hoito
Opintotyyppi
Ilmoittautuminen (Arvioitu)
Vaihe
- Ei sovellettavissa
Yhteystiedot ja paikat
Opiskeluyhteys
- Nimi: Tiziana Lazzarotto, MD
- Puhelinnumero: +39 0512143360
- Sähköposti: tiziana.lazzarotto@unibo.it
Tutki yhteystietojen varmuuskopiointi
- Nimi: Giulia Piccirilli, MD
- Sähköposti: giulia.piccirilli@aosp.bo.it
Opiskelupaikat
-
-
Italy
-
Bologna, Italy, Italia, 40138
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
-
-
Osallistumiskriteerit
Kelpoisuusvaatimukset
Opintokelpoiset iät
Hyväksyy terveitä vapaaehtoisia
Sukupuolet, jotka voivat opiskella
Kuvaus
Inclusion Criteria:
- CSE/SOT transplant patient;
- Currently receiving antiviral medication;
- Age ≥ 18 years
- Signed informed consent form for participation and data processing
Exclusion Criteria:
- Localized CMV infection / organ disease.
Opintosuunnitelma
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Ensisijainen käyttötarkoitus: Hoito
- Jako: Satunnaistettu
- Inventiomalli: Rinnakkaistehtävä
- Naamiointi: Ei mitään (avoin tarra)
Aseet ja interventiot
Osallistujaryhmä / Arm |
Interventio / Hoito |
|---|---|
|
Kokeellinen: Antiviral therapy will be discontinued after two consecutive negative results for CMV-RNAemia
|
From enrollment (time 0, t0) until viral clearance is achieved (tn), all remaining biological material from blood samples analyzed for the monitoring/diagnosis of CMV infection will be collected and stored. Plasma samples will be analyzed for the presence of UL21.5 mRNA (CMV-RNAemia UL21.5) using the automated CMV-RNA ELITe MGB kit on an InGenius instrument (ELITech Group). During the treatment period and the follow-up period, patients will be monitored in accordance with current clinical practice through serial virologic assessments (CMV-DNAemia) and the collection of relevant clinical data. Assessments will be conducted weekly during the first three months after transplantation, every 15 days from the fourth to the sixth month, and then monthly from the seventh to the twelfth month. For the purposes of evaluating the primary endpoint, the first four months of follow-up will be taken into account. |
|
Active Comparator: Antiviral therapy will be discontinued after two consecutive negative results for CMV-DNAemia
|
During the treatment period and the follow-up period, patients will be monitored in accordance with current clinical practice through serial virologic assessments (CMV-DNAemia) and the collection of relevant clinical data. Assessments will be conducted weekly during the first three months after transplantation, every 15 days from the fourth to the sixth month, and then monthly from the seventh to the twelfth month. For the purposes of evaluating the primary endpoint, the first four months of follow-up will be taken into account. |
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
CMV-DNAemia VS CMV-DNAemia 1
Aikaikkuna: Periprocedural
|
To determine whether the use of CMV-RNAemia to guide the discontinuation of antiviral therapy in transplant recipients (SOT and CSE) results in a reduction in the duration of treatment exposure compared to the standard strategy based on CMV-DNAemia, and a possible reduction in toxicity from anti-CMV drugs, without increasing the risk of recurrence of the infection. Measure: Time to discontinuation of therapy |
Periprocedural
|
|
CMV-DNAemia VS CMV-DNAemia 2
Aikaikkuna: Periprocedural
|
To determine whether the use of CMV-RNAemia to guide the discontinuation of antiviral therapy in transplant recipients (SOT and CSE) results in a reduction in the duration of treatment exposure compared to the standard strategy based on CMV-DNAemia, and a possible reduction in toxicity from anti-CMV drugs, without increasing the risk of recurrence of the infection. Measure: Time to viral clearance |
Periprocedural
|
|
CMV-DNAemia VS CMV-DNAemia 3
Aikaikkuna: Follow-up analysis (up to 4 months)
|
To determine whether the use of CMV-RNAemia to guide the discontinuation of antiviral therapy in transplant recipients (SOT and CSE) results in a reduction in the duration of treatment exposure compared to the standard strategy based on CMV-DNAemia, and a possible reduction in toxicity from anti-CMV drugs, without increasing the risk of recurrence of the infection. Measure: Incidence and time to recurrence of clinically significant CMV infection |
Follow-up analysis (up to 4 months)
|
|
CMV-DNAemia VS CMV-DNAemia 4
Aikaikkuna: Periprocedural
|
To determine whether the use of CMV-RNAemia to guide the discontinuation of antiviral therapy in transplant recipients (SOT and CSE) results in a reduction in the duration of treatment exposure compared to the standard strategy based on CMV-DNAemia, and a possible reduction in toxicity from anti-CMV drugs, without increasing the risk of recurrence of the infection. Measure: Toxicity associated with anti-CMV drugs |
Periprocedural
|
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Sanger sequencing VS NGS sequencing 1
Aikaikkuna: Follow up analysis (up to 1 year)
|
Evaluate the diagnostic performance of NGS sequencing compared to the Sanger method in identifying CMV mutations associated with drug resistance, including minor variants. Measure: Sensitivity and specificity of NGS compared to Sanger |
Follow up analysis (up to 1 year)
|
|
Incidence of refractory CMV infection
Aikaikkuna: Follow up analysis (up to 1 year)
|
To estimate the incidence of resistant or refractory CMV infection (R/R CMV) in transplant recipients (SOT and CSE). Measure: Incidence of resistant or refractory CMV infection |
Follow up analysis (up to 1 year)
|
|
Risk factors for refractory CMV infection
Aikaikkuna: Follow up analysis (up to 1 year)
|
To compare the risk factors associated with the development of resistant or refractory CMV infection (R/R CMV) by type of transplant. Measure: Risk factors associated with resistant or refractory CMV infection |
Follow up analysis (up to 1 year)
|
|
Sanger sequencing VS NGS sequencing 2
Aikaikkuna: Follow up analysis (up to 1 year)
|
Evaluate the diagnostic performance of NGS sequencing compared to the Sanger method in identifying CMV mutations associated with drug resistance, including minor variants. Measure: Predictive value of NGS compared to Sanger |
Follow up analysis (up to 1 year)
|
|
Sanger sequencing VS NGS sequencing 3
Aikaikkuna: Follow up analysis (up to 1 year)
|
Evaluate the diagnostic performance of NGS sequencing compared to the Sanger method in identifying CMV mutations associated with drug resistance, including minor variants. Measure: Time required to identify mutations using NGS compared to Sanger |
Follow up analysis (up to 1 year)
|
Yhteistyökumppanit ja tutkijat
Opintojen ennätyspäivät
Opi tärkeimmät päivämäärät
Opiskelun aloitus (Arvioitu)
Ensisijainen valmistuminen (Arvioitu)
Opintojen valmistuminen (Arvioitu)
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen Lähetetty (Todellinen)
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeksi vahvistettu
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Avainsanat
Muut tutkimustunnusnumerot
- CMV-TX-2025
- WFR 2802099 (Muu apuraha/rahoitusnumero: Italian Ministry of Health)
Yksittäisten osallistujien tietojen suunnitelma (IPD)
Aiotko jakaa yksittäisten osallistujien tietoja (IPD)?
Lääke- ja laitetiedot, tutkimusasiakirjat
Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta
Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .